Holen Sie sich die Stockscreener-App
27.90
0.96%
-0.27
Handel nachbörslich:
27.81
-0.09
-0.32%
Schlusskurs vom Vortag:
$28.17
Offen:
$28.1
24-Stunden-Volumen:
8.33M
Relative Volume:
0.57
Marktkapitalisierung:
$6.51B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
53.44
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-2.72%
1M Leistung:
-11.68%
6M Leistung:
+25.90%
1J Leistung:
-41.62%
1-Tages-Spanne:
$27.27
$28.28
1-Wochen-Bereich:
$27.27
$29.12
52-Wochen-Spanne:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.90 | 6.57B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.85 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.23 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.31 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.82 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Deadline Alert: Hims & Hers Health, Inc. (HIMS) - GlobeNewswire
Hims & Hers Health, Inc. • Robinhood Token (HIMS) Preț Azi - Bybit
HIMS Class Action Reminder – Robbins LLP Reminds Investors - GlobeNewswire
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report? - Yahoo Finance
Hims & Hers Health Stock (HIMS) Opinions on Regulatory Scrutiny and AI Potential - quiverquant.com
Is FTC Lawsuit Altering The Investment Case For Hims Stock (HIMS)? - simplywall.st
Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026 - NewMediaWire
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know - Yahoo Finance
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors Seeking Recovery to Contact the Firm Before November 2, 2026 - NewMediaWire
Hims & Hers stock: growth momentum versus margin pressure and a 20.6% fair value discount - Investing.com Canada
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Kaplan Fox Encourages Wix.com Ltd. (NASDAQ: WIX) Investors with Significant Losses to Contact the Firm Before September 22, 2026 - GlobeNewswire Inc.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Here's Why Teladoc's Integrated Care Business Deserves More Attention - TradingView
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Investors to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Inves - The National Law Review
INVESTOR DEADLINE ALERT: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion - Stocktwits
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc.HIMS - PR Newswire
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026 - NewMediaWire
ROSEN, LEADING TRIAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - ACCESS Newswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Hims & Hers - GlobeNewswire
DEADLINE ALERT for YSS, HIMS, and UNCY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - WBOC TV
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why - Fast Company
Investor relations - HIMS investor relations
FTC Hims and Hers Lawsuit: What the Telehealth Giant Didn't Want You to Know About Your Health Data - lawnews.co.uk
Hims & Hers Health, Inc. Securities Fraud Class Action Result of - The National Law Review
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm Before Lead Plaintiff Deadline on November 2, 2026 - newmediawire.com
Is Hims & Hers Health Inc (HIMS) a Bargain After 3.0% Drop? GF V - GuruFocus
Hims & Hers Health shares fall over 3% as sellers reinforce pressure and technical weakness persists - Traders Union
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Securities Class Action DeadlineContact the Firm Before November 2, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc.HIMS - PR Newswire
Jefferies Initiates Hims & Hers Health(HIMS.US) With Hold Rating, Announces Target Price $31 - Moomoo
HIMS Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Hims & Hers Health, Inc. - PR Newswire
Will Hims & Hers stock break $29.01 resistance as multiple securities fraud class actions filed? - Traders Union
Hims & Hers Health (NYSE: HIMS) Faces Securities Class - globenewswire.com
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE - The National Law Review
Hims & Hers Investor Sues Over FTC Privacy, Billing Claims - Law360
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm to Learn About Their Legal Rights - NewMediaWire
HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims & Hers Class Action Lawsuit - PR Newswire
Deadline Soon: Hims & Hers Health, Inc. (HIMS) Shareholders - GlobeNewswire
HIMS & HERS HEALTH, INC. (HIMS) INVESTOR ALERT Investors - GlobeNewswire
Hims & Hers Misled Investors Before FTC Pounced, Lawsuit Says - news.bloomberglaw.com
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):